Alison has served as a director since June 2015. She has over 25 years of experience in the development of investigational cancer chemotherapies. Since 2000, she has served as a consultant to the pharmaceutical industry, working with over 20 companies with a focus on molecularly targeted therapy. Prior to this, she worked as Senior Medical Director at SUGEN on various compounds, including SUTENT® (sunitinib malate), and Quintiles (now IQVIA), a global contract research organization.

With over 30 years of diagnostics and medical device experience, Neil has a comprehensive knowledge of the global diagnostic and sequencing markets. He brings direct experience of commercial operations; product launches; product development; clinical, quality, and regulatory processes; and strategy development.

Elizabeth has a track record for successfully leading technology and organizational transformation in highly matrixed environments. As Chief Information & Digital Officer of Numotion, she is managing a significant digital and cybersecurity transformation with the strategic use of data and technology to drive value creation by creating efficient and compliant operations. Before joining Numotion, she was the Global Vice President of Business Technology at Allergan (now part of AbbVie).

Lynn has served as a director since June 2015. She is founder and principal of Anahata Leadership, an advisory firm focused on supporting the leadership effectiveness and development of executive women. She worked from 1993 to 2014 with AstraZeneca, PLC, most recently as Executive Vice President, Human Resources and Corporate Affairs. Lynn was responsible for all human resources strategy, talent management, executive compensation and related activities, internal and external communications, government affairs, corporate reputation, and corporate social responsibility for the company.

Most recently, Kareem served as Chief Transformation Officer at GeneDx and was responsible for driving corporate strategy, corporate development, and emerging business initiatives to further accelerate the company’s growth. Prior to that, he served as Chief Strategy Officer at Sema4, leading the development of their long-term plan, spearheading their capital formation efforts, and eventually helping to take the company public in 2021 before leading the merger with GeneDx to transform the company into a leading rare disease diagnostic testing company.

Gary is responsible for Neo’s strategy regarding its most important asset — its people. Cultivating an engaging culture focused on how the company works in support of all teammates and customers is critical to the company’s success.

Nathan is the Vice President of Medical Services and the Medical Director for the NeoGenomics North Carolina laboratory. He joined NeoGenomics as the Director of Molecular Pathology Services in 2023, before taking on this current role in August 2024. Prior to joining NeoGenomics, he was a molecular pathologist and medical director at Tempus Laboratories and, prior to that, Director of Molecular Hematopathology at the University of North Carolina.

Hutan oversees the corporate compliance program across the NeoGenomics enterprise. He is a seasoned healthcare attorney, spending the last 12 years focusing on matters related to compliance, privacy, and regulatory challenges within the diagnostics industry. Most recently, Hutan served as Chief Compliance Officer at Progenity, Inc. (now Biora Therapeutics), a molecular diagnostics and device company, and was responsible for the company’s compliance with their Corporate Integrity Agreement, from implementation activities to successful execution under the terms of the agreement.

Warren Stone was appointed President and Chief Operating Officer of NeoGenomics in April 2025. He joined Neo in November 2022 as President, Clinical Services and later became Chief Commercial Officer. 

Warren is a highly accomplished enterprise leader with extensive global experience in the life science and diagnostic sectors, who most recently served as President of Americas at Ortho Clinical Diagnostics (now QuidelOrtho). 

Jeff has over 32 years of finance experience in the healthcare services industry, having gained a well-rounded background from serving in finance roles at public companies of different sizes and at different growth stages in their life cycle.